Oslo, September 20, 2018 - Overview of mandatory notification regarding exercise
and  trade of subscription rights. Management and  the board of directors of PCI
Biotech  Holding ASA ("PCI Biotech" or "the  Company") are all supportive to the
share  issue resolved by the extraordinary general meeting 14 September 2018. In
total  the transactions disclosed herein leads to a net increase in shareholding
by primary insiders of PCI Biotech of 53,348 shares.

The following transactions are made at 20 September 2018:
Per  Walday,  CEO,  has  subscribed  for  3,167 new  shares  in the Company at a
subscription  price of NOK 30 per  share by exercising 3,167 subscription rights
in  the Company's ongoing rights issue and has simultaneously sold his remaining
28,096 subscription  rights  at  an  average  price of NOK 4.71 per subscription
right.  The  sale  of  the  subscription  rights  are made to finance all of the
subscription  rights exercised. After  the transactions, Per  Walday will have a
total shareholding in the Company of 68,300 shares and 104,000 unexercised stock
options in relation to the Company's share option scheme.

Ronny  Skuggedal, CFO, has subscribed  for 3,234 new shares in  the Company at a
subscription  price of NOK 30 per  share by exercising 3,234 subscription rights
in  the Company's ongoing rights issue and has simultaneously sold his remaining
8,797 subscription  rights  at  an  average  price  of NOK 4.71 per subscription
right.  The sale  of the  subscription rights  are made  to finance parts of the
subscription  rights exercised. After the transaction, Ronny Skuggedal will have
a  total shareholding  in the  Company of  28,300 shares and 116,000 unexercised
stock options in relation to the Company's share option scheme.

Kristin  Eivindvik, PD, has  subscribed for 852 new  shares in the  Company at a
subscription  price of NOK 30 per share by exercising 852 subscription rights in
the  Company's ongoing  rights issue  and has  simultaneously sold her remaining
7,763 subscription  rights  at  an  average  price  of NOK 4.71 per subscription
right.  The  sale  of  the  subscription  rights  are made to finance all of the
subscription  rights exercised.  After the  transactions, Kristin Eivindvik will
have a total shareholding in the Company of 18,800 shares and 33,500 unexercised
stock options in relation to the Company's share option scheme.

Anders  Høgset,  CSO,  has  subscribed  for  844 new  shares in the Company at a
subscription  price of NOK 30 per share by exercising 844 subscription rights in
the  Company's ongoing  rights issue  and has  simultaneously sold his remaining
29,134 subscription  rights  at  an  average  price of NOK 4.71 per subscription
right.  After the transactions, Anders Høgset  will have a total shareholding in
the Company of 63,300 shares and 66,000 unexercised stock options in relation to
the Company's share option scheme.

Gaël  L'Hévéder, CBDO, has sold all  his 4,800 subscription rights at an average
price  of NOK 4.71 per subscription right. After the transaction, Gaël L'Hévéder
have  a  total  shareholding  in  the  Company  of  10,000 shares  and  106,000
unexercised stock options in relation to the Company's share option scheme.

In  addition,  the  following  transactions  were  made  by the chairman and two
members  of PCI Biotech's board of  directors at 19 September 2018 and disclosed
the same day.

The  Chairman Hans  Peter Bøhn  subscribed for  40,106 new shares in PCI Biotech
Holding  ASA  (the  "Company")  at  19 September  2018 (the transaction was also
disclosed  19 September 2018) at  a subscription  price of  NOK 30 per  share by
exercising all his 40,106 subscription rights allocated in the Company's ongoing
rights  issue.  After  the  transaction,  Hans  Peter  Bøhn  will  have  a total
shareholding in the Company of 123,662 shares.

The  board member Lars  Viksmoen subscribed for  1,920 new shares in PCI Biotech
Holding  ASA  (the  "Company")  at  19 September  2018 (the transaction was also
disclosed  19 September 2018) at  a subscription  price of  NOK 30 per  share by
exercising  all his 1,920 subscription rights allocated in the Company's ongoing
rights  issue through his wholly owned  company, Stocken Invest AS. In addition,
Stocken  Invest AS bought  1,580 subscription rights at  an average price of NOK
4.40 per  subscription  right  and  subsequently  exercised  the  1,580 acquired
subscription rights. After the transactions, Stocken Invest AS will have a total
shareholding  in the Company  of 7,500 shares. Stocken  Invest AS has previously
entered  into a guarantee  agreement of NOK  1,000,000 in relation to the rights
issue,  and the  exercise of  subscription rights  will, in  compliance with the
guarantee agreement, reduce the guarantee liability correspondingly.

The board member Christina Herder subscribed for 1,645 new shares in PCI Biotech
Holding  ASA (the "Company") at 19 September 2018 (the transaction was disclosed
the same day) at a subscription price of NOK 30 per share by exercising 1,645 of
her  allocated subscription  rights in  the Company's  ongoing rights  issue. In
addition,  she sold her remaining 2,365 subscription  rights at an average price
of  NOK 4.40 per subscription  right.  After the  transactions, Christina Herder
will have a total shareholding in the Company of 10,000 shares.

Reference  is  made  to  the  Prospectus  dated  17 September  2018 for  further
information about the terms of the rights issue.

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, NO-0379 Oslo.
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757.

This  information is subject to the  disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
